Your Yourlocation: Home > Compared tiotropium bromide(136310-93-5) inhalation by dry powder with Respimat soft mist inhalation by powder

The TIOSPIR trial compared tiotropium bromide(136310-93-5) inhalation with dry powder inhalation and Respimat inhalers, and the results showed no difference in mortality and acute exacerbation risk. The results of this large randomized controlled clinical trial responded strongly to previous meta-analyzes of doubts about safety.

(LAMA) as a medicament, aerosol duration is longer, extended to more than 1.2 seconds, aerosol spray speed is slow, the ideal particle content of up to 70%, to ensure the efficient deposition of drugs in the lungs, reaching 51.6%. In order to maintain the same effect in the case of reducing the dose of inhaled drugs provides the possibility. And the new device is simple to use, just "turn, open, press" three movements, patient compliance greatly improved.

COPD is a common and serious disease which seriously endangers human health. By 2020, COPD will rank 5th in economic burden of disease in the world and 3rd in the global cause of death. China's 20245 adults in seven regions to investigate, over the age of 40 people with chronic obstructive pulmonary disease prevalence rate of 8.2%.

Data from the National Heart, Lung, and Blood Institute show that many diseases (such as cerebrovascular disease and cancer) have a declining trend in morbidity and mortality through the effective implementation of tertiary prevention systems, with the exception of COPD showing a rapid upward trend. Therefore, COPD is increasingly subject to international and domestic society's widespread concern. The main goal of COPD treatment is to improve lung function, in addition to make full use of existing treatment, the urgent need to be updated treatment was developed.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved